Gain Therapeutics (GANX) Return on Assets (2021 - 2025)
Historic Return on Assets for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to 2.11%.
- Gain Therapeutics' Return on Assets fell 8200.0% to 2.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.11%, marking a year-over-year decrease of 8200.0%. This contributed to the annual value of 1.49% for FY2024, which is 4400.0% down from last year.
- Latest data reveals that Gain Therapeutics reported Return on Assets of 2.11% as of Q3 2025, which was down 8200.0% from 1.97% recorded in Q2 2025.
- Gain Therapeutics' 5-year Return on Assets high stood at 0.18% for Q2 2021, and its period low was 2.11% during Q3 2025.
- Over the past 5 years, Gain Therapeutics' median Return on Assets value was 1.11% (recorded in 2023), while the average stood at 1.02%.
- As far as peak fluctuations go, Gain Therapeutics' Return on Assets plummeted by -8400bps in 2023, and later soared by 800bps in 2024.
- Quarter analysis of 5 years shows Gain Therapeutics' Return on Assets stood at 0.34% in 2021, then plummeted by -97bps to 0.67% in 2022, then plummeted by -106bps to 1.38% in 2023, then decreased by -25bps to 1.73% in 2024, then dropped by -22bps to 2.11% in 2025.
- Its Return on Assets was 2.11% in Q3 2025, compared to 1.97% in Q2 2025 and 1.97% in Q1 2025.